Kalvista Pharmaceuticals Inc
NASDAQ:KALV
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.4
16.91
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Kalvista Pharmaceuticals Inc
Net Income (Common)
Kalvista Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Kalvista Pharmaceuticals Inc
NASDAQ:KALV
|
Net Income (Common)
-$109.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-16%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$2.3B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$8.1B
|
CAGR 3-Years
34%
|
CAGR 5-Years
45%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
23%
|
|
Kalvista Pharmaceuticals Inc
Glance View
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. The company is headquartered in Cambridge, Massachusetts and currently employs 70 full-time employees. The company went IPO on 2015-04-09. The firm is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The firm has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). Plasma kallikrein is a serine protease enzyme, which is an early mediator of inflammation and edema. The body modulates the inflammatory effects of plasma kallikrein through a circulating inhibitor protein called C1-esterase inhibitor (C1-INH). The firm is primary focused on the development of the oral plasma kallikrein inhibitors for HAE. The company has two drug program candidates in clinical trials. The Company’s DME program is focused on the development of an intravitreally administered small molecule plasma kallikrein inhibitor, KVD001, which completed a Phase II trial.
See Also
What is Kalvista Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-109.6m
USD
Based on the financial report for Sep 30, 2025, Kalvista Pharmaceuticals Inc's Net Income (Common) amounts to -109.6m USD.
What is Kalvista Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-16%
Over the last year, the Net Income (Common) growth was 30%. The average annual Net Income (Common) growth rates for Kalvista Pharmaceuticals Inc have been -6% over the past three years , -24% over the past five years , and -16% over the past ten years .